Peter Lawson's Stock Ratings

Barclays Analyst

Peter Lawson is an analyst at Barclays. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/16/2024

Overall Average Return

-7.52%

Smart Score

46.4%

Overall Average Return Percentile

23rd

Number of Ratings

59
Buy NowGet Alert
05/10/2024MGNXBuy Now
Macrogenics
$5.24167.18%$25 → $14MaintainsOverweightGet Alert
05/10/2024RLAYBuy Now
Relay Therapeutics
$6.51130.41%$15 → $15UpgradeEqual-Weight → OverweightGet Alert
05/03/2024BPMCBuy Now
Blueprint Medicines
$106.64-29.67%$70 → $75MaintainsEqual-WeightGet Alert
04/30/2024DCPHBuy Now
Deciphera Pharmaceuticals
$25.452.16%$9 → $26UpgradeUnderweight → Equal-WeightGet Alert
04/11/2024EXELBuy Now
Exelixis
$21.2917.43%$25 → $25DowngradeOverweight → Equal-WeightGet Alert
03/08/2024MGNXBuy Now
Macrogenics
$5.24377.1%$23 → $25MaintainsOverweightGet Alert
03/07/2024TCRXBuy Now
TScan Therapeutics
$8.901.12%$7 → $9MaintainsOverweightGet Alert
02/29/2024ARVNBuy Now
Arvinas
$32.1186.86%$26 → $60MaintainsOverweightGet Alert
02/29/2024IOVABuy Now
Iovance Biotherapeutics
$10.45110.53%$18 → $22MaintainsOverweightGet Alert
02/29/2024MGNXBuy Now
Macrogenics
$5.24338.93%$12 → $23MaintainsOverweightGet Alert
02/29/2024SWTXBuy Now
SpringWorks Therapeutics
$44.7740.72%$47 → $63MaintainsOverweightGet Alert
02/27/2024FATEBuy Now
Fate Therapeutics
$4.14141.55%$6 → $10MaintainsOverweightGet Alert
02/13/2024BPMCBuy Now
Blueprint Medicines
$106.64-34.36%$58 → $70MaintainsEqual-WeightGet Alert
01/30/2024EXELBuy Now
Exelixis
$21.2917.43%$24 → $25MaintainsOverweightGet Alert
01/25/2024SWTXBuy Now
SpringWorks Therapeutics
$44.774.98%$41 → $47MaintainsOverweightGet Alert
12/06/2023REPLBuy Now
Replimune Group
$6.7293.45%$50 → $13MaintainsOverweightGet Alert
12/04/2023IMGNBuy Now
Immunogen
——$27 → $31DowngradeOverweight → Equal-WeightGet Alert
12/01/2023IMGNBuy Now
Immunogen
———DowngradeOverweight → Equal-WeightGet Alert
10/27/2023BPMCBuy Now
Blueprint Medicines
$106.64-45.61%$46 → $58MaintainsEqual-WeightGet Alert
10/24/2023ARVNBuy Now
Arvinas
$32.11-19.03%$39 → $26MaintainsOverweightGet Alert
10/17/2023EXAIBuy Now
Exscientia
$5.2092.31%$12 → $10MaintainsOverweightGet Alert
09/18/2023IOVABuy Now
Iovance Biotherapeutics
$10.4572.25%$40 → $18MaintainsOverweightGet Alert
08/10/2023FATEBuy Now
Fate Therapeutics
$4.1444.93%$12 → $6MaintainsOverweightGet Alert
08/10/2023ADAPBuy Now
Adaptimmune Therapeutics
$1.16-13.79%$2 → $1MaintainsUnderweightGet Alert
08/09/2023ARVNBuy Now
Arvinas
$32.1121.46%$70 → $39MaintainsOverweightGet Alert
08/04/2023PRLDBuy Now
Prelude Therapeutics
$4.2019.05%$7 → $5MaintainsEqual-WeightGet Alert
08/03/2023EXELBuy Now
Exelixis
$21.2912.73%$25 → $24MaintainsOverweightGet Alert
08/02/2023IMGNBuy Now
Immunogen
——$20 → $27MaintainsOverweightGet Alert
07/26/2023SNDXBuy Now
Syndax Pharmaceuticals
$20.9262.52%$31 → $34MaintainsOverweightGet Alert
06/12/2023IMGNBuy Now
Immunogen
——$9 → $20MaintainsOverweightGet Alert